← FDA DRUG APPROVALS

FDA ANDA · ANDA207363

RUFINAMIDE

Sponsor: HIKMA

APPLICATION
ANDA207363
TYPE
ANDA
ORIGINAL APPROVAL
2019-04-23
LATEST ACTION
2020-08-07
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Prescription

Products

RUFINAMIDEPrescription
RUFINAMIDE 40MG/ML · SUSPENSION · ORAL

Approval history

2020-08-07Labeling · Supplement 1 · standardAP
2019-04-23UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →